Valbenazine
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia
Trial Timeline
Aug 29, 2025 → Apr 1, 2027
NCT ID
NCT07105111About Valbenazine
Valbenazine is a approved stage product being developed by Neurocrine Biosciences for Schizophrenia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07105111. Target conditions include Schizophrenia, Schizoaffective Disorder, Bipolar Disorder.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07105111 | Approved | Recruiting |
| NCT05053321 | Phase 1 | Withdrawn |
| NCT06312189 | Phase 3 | Recruiting |
| NCT05859698 | Approved | Completed |
| NCT04400331 | Phase 3 | Active |
| NCT03444038 | Phase 2 | Completed |
| NCT02879578 | Phase 2 | Completed |
| NCT02736955 | Phase 3 | Completed |
Competing Products
20 competing products in Schizophrenia